Dena Ramadan's questions to ITCI leadership • Q2 2024
Question
Speaking for Jason Gerberry, asked about ITI-1284, questioning if the Rexulti launch is a good comparison for the Alzheimer's disease space, the challenges of displacing generics, and how lumateperone could succeed against these barriers.
Answer
The company views the Rexulti launch as being in its early days and believes the market for treating agitation in Alzheimer's will take time to develop. They are confident that a product with a strong safety and tolerability profile like lumateperone has a large opportunity due to the significant unmet medical need.